Rupal P. O'Quinn, MD, MHCI, FACC
Associate Professor of Clinical Medicine (Cardiovascular Medicine)
Director of Cardio-Oncology, Penn Presbyterian Medical Center
Associate Program Director, Penn Cardiovascular Disease Fellowship Program, University of Pennsylvania
Department: Medicine
Contact information
Heart and Vascular Pavilion
51 N. 39th Street, 4th Floor
Philadelphia, PA 19104
51 N. 39th Street, 4th Floor
Philadelphia, PA 19104
Office: 215-662-9189
Education:
BS (Bachelor of Science in Human Physiology (Summa Cum Laude)
Boston University, Boston, Massachusetts, 2002.
MD (Doctor of Medicine)
Rutgers Medical School/University of Medicine and Dentistry of New Jersey, 2007.
MHCI (Master of Health Care Innovation)
University of Pennsylvania, 2023.
Permanent linkBS (Bachelor of Science in Human Physiology (Summa Cum Laude)
Boston University, Boston, Massachusetts, 2002.
MD (Doctor of Medicine)
Rutgers Medical School/University of Medicine and Dentistry of New Jersey, 2007.
MHCI (Master of Health Care Innovation)
University of Pennsylvania, 2023.
Description of Clinical Expertise
Cardiac complications of cancer treatment, echocardiography, cardiac magnetic resonance, healthcare innovationDescription of Research Expertise
Cardiac complications of cancer treatment; Health Care InnovationSelected Publications
Chen YC, Miranda P, Barqawi YK, Fox GE, Chukwu C, Moslehi J, O’Quinn RP: Cardiovascular safety outcomes of chronic lymphocytic leukemia treatments: A systematic and targeted literature review. Crit Rev Oncol Hematol. August 2025.Lenihan D, Bloom M, Copeland-Halperin R, Fleming MR, Fradley M, O'Quinn R, Bhat SA.: Considerations for the Practical Management of Cardiovascular Risk With Bruton's Tyrosine Kinase Inhibitors for Patients With CLL. Oncologist July 2025.
Tripathi S, O’Quinn R, Cook TS: Cardiothoracic Imaging AI for Cardiac Diseases. Semin Roentgenol. July 2025.
O’Quinn RP, Desai NR, Dhruva S, Ptaszek LM, Pundi K.: Leveraging Apple Watch for Cardiovascular Care. Accessed August 4, 2025. https://www.acc.org/LeveragingAppleWatch. May 2025.
O'Quinn R, Corry AJ, Bajwa N, Jannuru S, Chen H, Miranda P, Brown JR.: Cardiac Events in Three Phase 3 Randomized Trials Including Acalabrutinib in Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk. April 2025.
Pepe V, Afari H, O'Quinn RP, Arjoon R: Burkholderia cepacia Endocarditis in a Patient With Severe Mitral Annular Calcification. JACC Case Reports August 2024.
Vallabhaneni S, Adusumalli S, Wu J, Groeneveld PW, Gerson J, O'Quinn RP. : Cardiotoxicity from bruton tyrosine kinase inhibitors (BTKi)-an analysis of an administrative health claims database. Cardiooncology June 2024.
Yegya-Raman N, Ho Lee S, Friedes C, Wang X, Iocolano M, Kegelman TP, Duan L, Li B, Berlin E, Kim KN, Doucette A, Denduluri S, Levin WP, Cengel KA, Cohen RB, Langer CJ, Kevin Teo BK, Zou W, O'Quinn RP, Deasy JO, Bradley JD, Sun L, Ky B, Xiao Y, Feigenberg SJ.: Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidation. Radiother Oncol. 2024 2024.
Yegya-Raman N, Kegelman TP, Ho Lee S, Kallan MJ, Kim KN, Natarajan J, Deek MP, Zou W, O'Reilly SE, Zhang Z, Levin W, Cengel K, Kao G, Cohen RB, Sun LL, Langer CJ, Aggarwal C, Singh AP, O'Quinn R, Ky B, Apte A, Deasy J, Xiao Y, Berman AT, Jabbour SK, Feigenberg SJ: Death without progression as an endpoint to describe cardiac radiation effects in locally advanced non-small cell lung cancer. Clin Transl Radiat Oncol. January 2023.
Fanaroff AC, Coratti S, Halaby R, Sanghavi M, O'Quinn RP, Krishnan S, Glassberg H, Bajaj A, Adusumalli S, Chokshi N, Patel MS. : Feasibility and outcomes from using a commitment devices and text message reminders to increase adherence to time-restricted eating: A randomized trial. Am Heart J. January 2023.